Clinical Cohort Study on the Endocrinology and Vaginal/Endometrial Microbiome of the Luteal Phase in Assisted Reproduction

NCT ID: NCT03507673

Last Updated: 2025-05-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-05-02

Study Completion Date

2028-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rationale:

The hormone progesterone has different functions. In pregnancy, it is vital for maintenance thereof. In early pregnancy, progesterone is synthesized by the Corpus luteum (CL). Its production shifts from the CL to the placenta after several gestational weeks. This process is termed luteoplacental shift. Still, the exact time point of the luteoplacental shift remains unknown. Furthermore, the characteristics of placental progesterone increase and its relevance for the course of pregnancy has not been studied so far.

Furthermore, recent studies have shown an influence of abnormal vaginal microbiota on the likelihood to achieve and maintain pregnancy. Little is known about possible crosslinks between endocrinology and vaginal/endometrial microbiota which is why this study aims to investigate possible associations of such kind.

Objective:

The primary objective of this study is to evaluate the time point of the luteoplacental shift in patients achieving pregnancy after transfer of cryopreserved embryos subsequently to IVF/ICSI cycles. Secondary objectives are to study the characteristics of the placental progesterone increase and its function as a predictor of the course and development of pregnancies and to study vaginal/endometrial microbiota at baseline and changes associated with shift into luteal phase and early pregnancy and how this potentially relates to pregnancy outcome.

Study Design:

Prospective, multi-center, observational clinical cohort study. For the primary objective, data from a single center will be also be retrospectively analyzed.

Study population:

Female patients aged 18 to 45 years undergoing transfer of embryos after freezing and thawing 2PN oocytes or embryos.

Interventions: Blood withdrawal, vaginal/endometrial swabs and endocrine and microbiom analyses.

Study parameters/endpoints:

The main parameter is time point of progesterone increase in pregnancy in relation to initial progesterone levels by pregnancy status. Secondary, slope and magnitude of placental progesterone increase and its relevance as a predictor for the course and development of pregnancies/babies. Furthermore, vaginal microbiota of women undergoing embryo transfer and of women in early pregnancy are parameter of this study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Introduction and rationale Progesterone is a steroid hormone with different functions. In the luteal phase of the menstrual cycle elevated progesterone levels maintain the endometrium. Amongst others it stimulates glandular secretion and adjusts pattern of secreted proteins of the endometrium to provide a supportive environment for of embryo implantation. A sudden decline in progesterone levels leads to endometrial shedding and thereby menstrual bleeding. Thus, elevated progesterone levels are vital to maintain a pregnancy after successful embryo implantation. Progesterone is produced by the Corpus luteum (CL), a relict of the Graaf follicle, after ovulation in the luteal phase of the menstrual cycle and in the first weeks of pregnancy. The lifespan of the CL is assumed to be several weeks.

Before luteolysis of the CL, the production of progesterone shifts from the CL to the placenta which ensures maintenance of the pregnancy. This process is termed luteoplacental shift. Adequate placental progesterone increase is vital for the maintenance of the pregnancy and low progesterone levels can indicate inadequate development of early pregnancies. However, laboratory measurement of progesterone by conventional ELISA techniques cannot distinguish between placental progesterone and progesterone produced by the CL.

This is one reason why still little is known about the exact time point of the luteoplacental shift. In 1972 a decline of progesterone and subsequent loss of pregnancy for n=12 patients after ovariectomy or luteectomy in the 8th week of gestation but not for operations taking place in the 9th week of gestation (n= 5 patients) was reported. This is in line with in-vitro measurements from 1985 in a placental organ culture which shows the capability for progesterone production between 6th and 8th week of gestation. In 1990 it was observed in women (n=17) with absent of ovaries and constant exogenous progesterone administration achieving pregnancy by an egg donation program a significant progesterone increase in the 9th gestational week. This is in contrast to a study in a similar setting from 1991 in n=9 women who reported onset of endogenous progesterone production around the 5th week of gestation. Additionally, even the existence of the luteoplacental shift itself was questioned because of a wide range of progesterone levels observed in women achieving successful pregnancies by assisted reproduction technique (ART).

Moreover, 17-OH progesterone (17-OHP) was suspected to be produced solely by the CL in early pregnancy. This is supported by a study who found 17-OHP blood levels and vascularity of the CL decreasing from 5th till 11th week of gestation suggesting the luteoplacental shift to take place.

In summary, little is known about the exact time point of the luteoplacental shift.

Secondly, to date the slope and magnitude of the placental progesterone increase and its relevance as indicator for the latter course of the pregnancy has not been properly studied.

In routine care patients undergoing transfer of cryopreserved embryos subsequently to an IVF/ICSI cycle use estradiol and progesterone supplementation to ensure anovulation during the menstrual cycle for optimal timing of embryo transfer. For long the vaginal application of micronized progesterone have been standard of care for this purpose. In March 2017 the LOTUS I trial showed non-inferiority for oral intake (3 x 10 mg) of dydrogesterone, a retroprogesterone, a same safety profile and a higher live birth rate of approximately +5% versus micronized vaginal progesterone for patients undergoing ART. These findings are supported by a Cochrane review comprising 94 randomized trials. Therefore, in routine care the standard regime for luteal support (LPS) for all ART patients was changed to oral intake of 30 mg dydrogesterone daily at the Department of Gynecological Endocrinology and Reproductive Medicine of the University of Luebeck.

Unlike micronized progesterone the chemical properties of dydrogesterone preclude detection in laboratory progesterone measurement apart from a small fraction of cross-reactivities. This circumstance allows an analysis of endogenous progesterone despite supplementation of dihydrogesteron at the same time.

In patients undergoing transfer of cryopreserved embryos utilization of a dydrogesterone regime for LPS provides the unique opportunity to study in detail the time point and magnitude of endogenous progesterone production (i.e. the luteal shift). The choice of protocol (supplementation with exogenous sex steroids or natural cycle) is taken, when the treatment is planned based on regularity of the cycle and patient preferences.

Recent studies have shown an influence of abnormal vaginal microbiota for the prediction of pregnancy and for preclinical pregnancy loss in IVF treatment. Therefore, this study aims to investigates possible crosslinks between endocrine profile, vaginal and endometrial microbiota and the establishment and maintenance of pregnancy.

Furthermore, possible differences in vaginal bleeding pattern between different groups of cryopreservation regimes have not been evaluated so far. This study aims to investigate whether vaginal bleeding patterns might be influenced the cryopreservation regime.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infertility

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Progynova/Dydrogesterone

Blood samples and microbiological swaps

Intervention Type DIAGNOSTIC_TEST

Blood analysis and analysis of vaginal microbiota.

Spontaneous cycle

Blood samples and microbiological swaps

Intervention Type DIAGNOSTIC_TEST

Blood analysis and analysis of vaginal microbiota.

Progynova/Crinone

Blood samples and microbiological swaps

Intervention Type DIAGNOSTIC_TEST

Blood analysis and analysis of vaginal microbiota.

Others Medication

Blood samples and microbiological swaps

Intervention Type DIAGNOSTIC_TEST

Blood analysis and analysis of vaginal microbiota.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood samples and microbiological swaps

Blood analysis and analysis of vaginal microbiota.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients aged 18 to 45 years
2. Transfer of cryopreserved embryos

Exclusion Criteria

1. Fresh IVF/ICSI embryo transfer cycle
2. Evidence for ovulation on ultrasound previous to embryo transfer confirmed by a follicle ≥14mm or by a progesterone ≥1.0 µg/l in programmed cycles
3. Uterus malformations, endometrial abnormalities (on ultrasound or diagnosed by previous hysteroscopy)
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Luebeck

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Prof. Dr. med. M.Sc. Georg Griesinger

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Georg Griesinger, MD

Role: PRINCIPAL_INVESTIGATOR

Sektion für gynäkologische Endokrinologie und Reproduktionsmedizin

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

IVF-SAAR

Saarbrücken, Saarland, Germany

Site Status RECRUITING

Universitäres Kinderwunschzentrum Lübeck

Lübeck, Schleswig-Holstein, Germany

Site Status RECRUITING

Universitätsklinikum Düsseldorf,UniKiD

Düsseldorf, , Germany

Site Status RECRUITING

Universitäres Kinderwunschzentrum

Kiel, , Germany

Site Status RECRUITING

University of Luebeck

Lübeck, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Georg Griesinger, MD

Role: CONTACT

+49451 50577810

Tanja Eggersmann, MD

Role: CONTACT

+49451 50577810

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sascha Tauchert, MD

Role: primary

0681-93632-0

Lars Happel, MD

Role: backup

0681-93632-0

Georg Griesinger, Prof Dr MSc

Role: primary

+49 451 50577810

Tanja Eggersmann, MD

Role: backup

+49 451 50577810

Philippos Edimiris, MD

Role: primary

+49 211 81-04060

Jan S Krüssel, Prof. Dr.

Role: backup

+49 211 81-04060

Sören von Otte, PD Dr.

Role: primary

0431 500-92220

Georg Griesinger, MD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Rommler A, Kreuzer E. [Endocrinologic aspects of habitual abortion]. Zentralbl Gynakol. 2001 Jun;123(6):344-52. doi: 10.1055/s-2001-16284. German.

Reference Type BACKGROUND
PMID: 11488162 (View on PubMed)

Csapo AI, Pulkkinen MO, Ruttner B, Sauvage JP, Wiest WG. The significance of the human corpus luteum in pregnancy maintenance. I. Preliminary studies. Am J Obstet Gynecol. 1972 Apr 15;112(8):1061-7. doi: 10.1016/0002-9378(72)90181-0.

Reference Type BACKGROUND
PMID: 5017636 (View on PubMed)

Ogino M. Productivity of estrogens by human placental organ culture at different stages of gestation. Endocrinol Jpn. 1985 Oct;32(5):607-13. doi: 10.1507/endocrj1954.32.607.

Reference Type BACKGROUND
PMID: 4092668 (View on PubMed)

Devroey P, Camus M, Palermo G, Smitz J, Van Waesberghe L, Wisanto A, Wijbo I, Van Steirteghem AC. Placental production of estradiol and progesterone after oocyte donation in patients with primary ovarian failure. Am J Obstet Gynecol. 1990 Jan;162(1):66-70. doi: 10.1016/0002-9378(90)90822-o.

Reference Type BACKGROUND
PMID: 2154102 (View on PubMed)

Scott R, Navot D, Liu HC, Rosenwaks Z. A human in vivo model for the luteoplacental shift. Fertil Steril. 1991 Sep;56(3):481-4. doi: 10.1016/s0015-0282(16)54544-0.

Reference Type BACKGROUND
PMID: 1894025 (View on PubMed)

Azuma K, Calderon I, Besanko M, MacLachlan V, Healy DL. Is the luteo-placental shift a myth? Analysis of low progesterone levels in successful art pregnancies. J Clin Endocrinol Metab. 1993 Jul;77(1):195-8. doi: 10.1210/jcem.77.1.7686913.

Reference Type BACKGROUND
PMID: 7686913 (View on PubMed)

Tulchinsky D, Simmer HH. Sources of plasma 17alpha-hydroxyprogesterone in human pregnancy. J Clin Endocrinol Metab. 1972 Dec;35(6):799-808. doi: 10.1210/jcem-35-6-799. No abstract available.

Reference Type BACKGROUND
PMID: 4634481 (View on PubMed)

Jarvela IY, Ruokonen A, Tekay A. Effect of rising hCG levels on the human corpus luteum during early pregnancy. Hum Reprod. 2008 Dec;23(12):2775-81. doi: 10.1093/humrep/den299. Epub 2008 Aug 10.

Reference Type BACKGROUND
PMID: 18694877 (View on PubMed)

Tournaye H, Sukhikh GT, Kahler E, Griesinger G. A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Hum Reprod. 2017 May 1;32(5):1019-1027. doi: 10.1093/humrep/dex023.

Reference Type BACKGROUND
PMID: 28333318 (View on PubMed)

van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2015 Jul 7;2015(7):CD009154. doi: 10.1002/14651858.CD009154.pub3.

Reference Type BACKGROUND
PMID: 26148507 (View on PubMed)

Haahr T, Jensen JS, Thomsen L, Duus L, Rygaard K, Humaidan P. Abnormal vaginal microbiota may be associated with poor reproductive outcomes: a prospective study in IVF patients. Hum Reprod. 2016 Apr;31(4):795-803. doi: 10.1093/humrep/dew026. Epub 2016 Feb 23.

Reference Type BACKGROUND
PMID: 26911864 (View on PubMed)

van Oostrum N, De Sutter P, Meys J, Verstraelen H. Risks associated with bacterial vaginosis in infertility patients: a systematic review and meta-analysis. Hum Reprod. 2013 Jul;28(7):1809-15. doi: 10.1093/humrep/det096. Epub 2013 Mar 29.

Reference Type BACKGROUND
PMID: 23543384 (View on PubMed)

Graspeuntner S, Bohlmann MK, Gillmann K, Speer R, Kuenzel S, Mark H, Hoellen F, Lettau R, Griesinger G, Konig IR, Baines JF, Rupp J. Microbiota-based analysis reveals specific bacterial traits and a novel strategy for the diagnosis of infectious infertility. PLoS One. 2018 Jan 9;13(1):e0191047. doi: 10.1371/journal.pone.0191047. eCollection 2018.

Reference Type BACKGROUND
PMID: 29315330 (View on PubMed)

Gellersen B, Brosens JJ. Cyclic decidualization of the human endometrium in reproductive health and failure. Endocr Rev. 2014 Dec;35(6):851-905. doi: 10.1210/er.2014-1045. Epub 2014 Aug 20.

Reference Type RESULT
PMID: 25141152 (View on PubMed)

Di Renzo GC, Giardina I, Clerici G, Brillo E, Gerli S. Progesterone in normal and pathological pregnancy. Horm Mol Biol Clin Investig. 2016 Jul 1;27(1):35-48. doi: 10.1515/hmbci-2016-0038.

Reference Type RESULT
PMID: 27662646 (View on PubMed)

Neumann K, Masuch A, Vonthein R, Depenbusch M, Schultze-Mosgau A, Eggersmann TK, Griesinger G. Dydrogesterone and 20alpha-dihydrodydrogesterone plasma levels on day of embryo transfer and clinical outcome in an anovulatory programmed frozen-thawed embryo transfer cycle: a prospective cohort study. Hum Reprod. 2022 May 30;37(6):1183-1193. doi: 10.1093/humrep/deac045.

Reference Type DERIVED
PMID: 35323905 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Aktenzeichen: 18-005

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.